BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,029 filers reported holding BAXTER INTL INC in Q4 2014. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $409,234,000 | -7.4% | 9,229,459 | -0.6% | 0.08% | -17.6% |
| Q3 2016 | $442,083,000 | +3.1% | 9,287,455 | -2.1% | 0.09% | -4.2% |
| Q2 2016 | $428,900,000 | +19.5% | 9,484,736 | +8.6% | 0.10% | +14.5% |
| Q1 2016 | $358,834,000 | +15.9% | 8,735,003 | +7.6% | 0.08% | +16.9% |
| Q4 2015 | $309,601,000 | +17.6% | 8,115,369 | +1.2% | 0.07% | +4.4% |
| Q3 2015 | $263,332,000 | -55.1% | 8,016,209 | -4.5% | 0.07% | -51.8% |
| Q2 2015 | $587,086,000 | +5.7% | 8,395,333 | +3.6% | 0.14% | +6.0% |
| Q1 2015 | $555,216,000 | +4.4% | 8,105,347 | +11.7% | 0.13% | +1.5% |
| Q4 2014 | $531,656,000 | +8.1% | 7,254,143 | +5.9% | 0.13% | -5.8% |
| Q3 2014 | $491,741,000 | +4.5% | 6,851,626 | +5.3% | 0.14% | +5.3% |
| Q2 2014 | $470,507,000 | -2.3% | 6,507,704 | -0.6% | 0.13% | -7.7% |
| Q1 2014 | $481,761,000 | +14.2% | 6,547,451 | +7.9% | 0.14% | +11.7% |
| Q4 2013 | $421,973,000 | +18.8% | 6,067,193 | +12.2% | 0.13% | +6.7% |
| Q3 2013 | $355,266,000 | -2.9% | 5,408,227 | +2.3% | 0.12% | -10.4% |
| Q2 2013 | $366,035,000 | – | 5,284,185 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |